Who are UFH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Unfractionated heparin(UFH).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ufh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

UFH — Competitive Intelligence Brief

UFH (UFH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low molecular weight heparin. Area: Cardiovascular.

phase 3 Low molecular weight heparin Antithrombin III Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

UFH (UFH) — VarmX B.V.. UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UFH TARGET	UFH	VarmX B.V.	phase 3	Low molecular weight heparin	Antithrombin III
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Unfractionated heparin(UFH)	Unfractionated heparin(UFH)	Beijing Chao Yang Hospital	marketed	Anticoagulant	Antithrombin III (enhancer); Factor IIa (thrombin) and Factor Xa (indirect targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low molecular weight heparin class)

Aalborg University Hospital · 1 drug in this class
Queen Mary University of London · 1 drug in this class
Rajaie Cardiovascular Medical and Research Center · 1 drug in this class
VarmX B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UFH — Competitive Intelligence Brief. https://druglandscape.com/ci/ufh. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab